Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer

Published:2020-03 Issue:3 Volume:12 Page:1079-1084
ISSN:2072-1439
Container-title:Journal of Thoracic Disease
language:
Short-container-title:J Thorac Dis

Author:

Masuda Takeshi,Fujitaka Kazunori,Ishikawa Nobuhisa,Nakano Kikuo,Yamasaki Masahiro,Kitaguchi Souichi,Masuda Ken,Yamaguchi Kakuhiro,Sakamoto Shinjiro,Horimasu Yasushi,Kawase Shigeo,Miyamoto Shintaro,Nakashima Taku,Iwamoto Hiroshi,Shiota Naoki,Senoo Tadashi,Awaya Yoshikazu,Kondo Tomohiro,Yoshida Takashi,Hamada Hironobu,Murakami Isao,Hattori Noboru

Publisher

AME Publishing Company

Subject

Pulmonary and Respiratory Medicine

Link

http://jtd.amegroups.com/article/download/34848/pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1;Thoracic Cancer;2022-04-30

2. Pembrolizumab-associated autoimmune encephalitis in an elderly patient with advanced non-small cell lung cancer. A clinical case;Anales del Sistema Sanitario de Navarra;2021-08-20

3. Immunotherapy in elderly patients;Meditsinskiy sovet = Medical Council;2021-08-07

4. Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV;Lung Cancer;2020-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP